Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer.
Br J Cancer
; 114(2): 134-7, 2016 Jan 19.
Article
en En
| MEDLINE
| ID: mdl-26730577
ABSTRACT
BACKGROUND:
The majority (90%) of anal cancers are human papillomavirus (HPV)-driven, identified using immunochemistry for p16. Compared with HPV- patients, those with HPV+ disease generally show improved survival, although relapse rates around 25% indicate a need for further stratification of this group.METHODS:
Using two cohorts of anal cancer, previously characterised for p16, we assessed the prognostic value of tumour-infiltrating lymphocytes (TILs).RESULTS:
Tumour-infiltrating lymphocyte scores were used to stratify p16+ cases, where tumours with absent/low levels of TIL had a relapse-free rate of 63%, as opposed to 92% with high levels of TIL (log rank P=0.006).CONCLUSIONS:
Assessment of TIL adds to p16 status in the prognosis of anal cancer following chemo-radiotherapy and provides evidence of the clinical importance of the immune response.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias del Ano
/
Carcinoma de Células Escamosas
/
Linfocitos Infiltrantes de Tumor
/
Infecciones por Papillomavirus
/
Proteínas de Neoplasias
Tipo de estudio:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
Br J Cancer
Año:
2016
Tipo del documento:
Article
País de afiliación:
Reino Unido